Pathology reporting of malignant pleural mesothelioma first diagnosis: A population-based approach

被引:10
作者
Ascoli, Valeria [1 ]
Minelli, Giada [2 ]
Cozzi, Ilaria [3 ]
Romeo, Elisa [3 ]
Scalzo, Caterina Carnovale [3 ]
Ancona, Laura [3 ]
Forastiere, Francesco [3 ]
机构
[1] Sapienza Univ, Dept Radiol Oncol & Anatomopathol Sci, Viale Regina Elena 324, I-00161 Rome, Italy
[2] Ist Super Sanita, Italys Inst Publ Hlth, Unit Stat, Viale Regina Elena 299, I-00161 Rome, Italy
[3] Lazio Reg Hlth Serv, Dept Epidemiol, Via Cristoforo Colombo 112, I-00147 Rome, Italy
关键词
Malignant pleural mesothelioma; Pathology reporting; Immunohistochemistry; Diagnosis; Cancer registry; EPITHELIOID MESOTHELIOMA; MINIMAL PANEL; IMMUNOHISTOCHEMISTRY; GUIDELINES; CANCER; ANTIBODIES; RECOMMENDATIONS; ADENOCARCINOMA; CONTROVERSIES; EXPRESSION;
D O I
10.1016/j.prp.2016.07.010
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Accurate pathologic diagnosis and reporting in malignant pleural mesothelioma are essential for clinical care, and cancer registration. Practical guidelines for pathologists are provided in publications and textbooks but it is unclear how these recommendations are applied in routine practice. We investigated the characteristics of pathology reports, and the extent to which they meet guideline standards. We reviewed 819 pathology reports relating to a first diagnosis of malignant pleural mesothelioma. Data sources were a regional section of the Italian network of the Mesothelioma Registry (2001-2014) and a pathology archive (1990-2000). We evaluated tumor characteristics, the diagnosis field including terminology and immunohistochemistry (IHC) workup, and report completeness (the proportion of items recorded). We investigated also two IHC panels identified by the most used markers in current practical guidelines, one best suited for epithelioid mesotheliomas (combinations of at least 2 positive and at least 2 negative mesothelioma markers) and the other best suited for sarcomatoid mesotheliomas (positive mesothelioma markers plus cytokeratins). Reports (753 histology, 66 cytology, IHC-confirmed 86%) were 74% complete and always narrative. Missing data were related to clinical history (76%), tumor laterality (61%), specimen size (38%), and histological subtype (23%). The proportion of cases with IHC was higher for epithelioid (90%) than sarcomatoid mesothelioma (87%). Compliance to IHC recommendations was higher for epithelioid (59%) than sarcomatoid mesothelioma (11%). The mean number of stains was significantly higher for sarcomatoid than epithelioid mesothelioma (p<0.000; Kruskal-Wallis test). Our findings show that although guidelines are designed to improve actual reporting practices, there is ample room for improvement in their application to standardize the diagnosis of mesothelioma. Synoptic pathology reporting needs to be implemented to better utilize pathology information. (C) 2016 Elsevier GmbH. All rights reserved.
引用
收藏
页码:886 / 892
页数:7
相关论文
共 50 条
  • [21] Surgical aspects of malignant pleural mesothelioma. From the perspective of pathology
    Fisseler-Eckhoff, A.
    CHIRURG, 2013, 84 (06): : 479 - 486
  • [22] Endobronchial ultrasound in the diagnosis of malignant pleural mesothelioma
    Guinde, J.
    Laroumagne, S.
    Kaspi, E.
    Martinez, S.
    Tazi-Mezalek, R.
    Astoul, P.
    Dutau, H.
    REVUE DES MALADIES RESPIRATOIRES, 2015, 32 (07) : 750 - 754
  • [23] Perspective on malignant pleural mesothelioma diagnosis and treatment
    Wald, Ori
    Sugarbaker, David J.
    ANNALS OF TRANSLATIONAL MEDICINE, 2016, 4 (06)
  • [24] Soluble markers for diagnosis of malignant pleural mesothelioma
    Cristaudo, Alfonso
    Bonotti, Alessandra
    Simonini, Silvia
    Bruno, Rossella
    Foddis, Rudy
    BIOMARKERS IN MEDICINE, 2011, 5 (02) : 261 - 273
  • [25] Chinese expert consensus on the diagnosis and treatment of malignant pleural mesothelioma
    Wang, Qian
    Xu, Chunwei
    Wang, Wenxian
    Zhang, Yongchang
    Li, Ziming
    Song, Zhengbo
    Wang, Jiandong
    Yu, Jinpu
    Liu, Jingjing
    Zhang, Shirong
    Cai, Xiuyu
    Li, Wen
    Zhan, Ping
    Liu, Hongbing
    Lv, Tangfeng
    Miao, Liyun
    Min, Lingfeng
    Li, Jiancheng
    Liu, Baogang
    Yuan, Jingping
    Jiang, Zhansheng
    Lin, Gen
    Chen, Xiaohui
    Pu, Xingxiang
    Rao, Chuangzhou
    Lv, Dongqing
    Yu, Zongyang
    Li, Xiaoyan
    Tang, Chuanhao
    Zhou, Chengzhi
    Zhang, Junping
    Guo, Hui
    Chu, Qian
    Meng, Rui
    Liu, Xuewen
    Wu, Jingxun
    Hu, Xiao
    Zhou, Jin
    Zhu, Zhengfei
    Chen, Xiaofeng
    Pan, Weiwei
    Pang, Fei
    Zhang, Wenpan
    Jian, Qijie
    Wang, Kai
    Wang, Liping
    Zhu, Youcai
    Yang, Guocai
    Lin, Xinqing
    Cai, Jing
    THORACIC CANCER, 2023, 14 (26) : 2715 - 2731
  • [26] Advances in malignant pleural mesothelioma: Diagnosis, treatment, and molecular mechanisms
    Mastromarino, Maria Giovanna
    Aprile, Vittorio
    Lucchi, Marco
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [27] MicroRNAs for the Diagnosis and Management of Malignant Pleural Mesothelioma: A Literature Review
    Lo Russo, Giuseppe
    Tessari, Anna
    Capece, Marina
    Galli, Giulia
    de Braud, Filippo
    Garassino, Marina Chiara
    Palmieri, Dario
    FRONTIERS IN ONCOLOGY, 2018, 8
  • [28] Validation of a minimal panel of antibodies for the diagnosis of malignant pleural mesothelioma
    Kao, Steven Chuan-Hao
    Griggs, Kim
    Lee, Kenneth
    Armstrong, Nicola
    Clarke, Stephen
    Vardy, Janette
    van Zandwijk, Nico
    Burn, Juliet
    McCaughan, Brian C.
    Henderson, Douglas W.
    Klebe, Sonja
    PATHOLOGY, 2011, 43 (04) : 313 - 317
  • [29] Endoscopic diagnosis and management of pleural effusion in malignant pleural mesothelioma
    Ceruti, Paolo
    Lonni, Sara
    Baglivo, Francesca
    Marchetti, Giampietro
    JOURNAL OF THORACIC DISEASE, 2018, 10 : S269 - +
  • [30] The Use of Immunohistochemistry, Fluorescencein situHybridization, and Emerging Epigenetic Markers in the Diagnosis of Malignant Pleural Mesothelioma (MPM): A Review
    Rozitis, Eric
    Johnson, Ben
    Cheng, Yuen Yee
    Lee, Kenneth
    FRONTIERS IN ONCOLOGY, 2020, 10